Free Trial
→ The Trump Dump is starting; Get out of stocks now? (From Paradigm Press) (Ad) Buy IOVA Stock  Free IOVA Stock Alerts

Iovance Biotherapeutics (IOVA) Financials

Iovance Biotherapeutics logo
$1.91 +0.08 (+4.37%)
Closing price 05/20/2025 04:00 PM Eastern
Extended Trading
$1.88 -0.03 (-1.57%)
As of 08:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Iovance Biotherapeutics

Annual Income Statements for Iovance Biotherapeutics

This table shows Iovance Biotherapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Net Income / (Loss) Attributable to Common Shareholders		 -372 -444 -396 -342 -260 -198 -124 -92 -102 -28 -12
Consolidated Net Income / (Loss)		 -372 -444 -396 -342 -260 -198 -124 -92 -53 -28 -12
Net Income / (Loss) Continuing Operations		 -372 -444 -396 -342 -260 -198 -124 -92 -53 -28 -12
Total Pre-Tax Income 		-375 -448 -396 -342 -260 -198 -124 -92 -53 -28 -12
Total Operating Income		 -395 -461 -399 -343 -262 -207 -128 -93 -54 -28 -12
Total Gross Profit		 40 -9.57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 164 1.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Revenue		 164 1.19 0.00 0.00 - - - - 0.00 0.00 0.00
Total Cost of Revenue		 124 11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cost of Revenue		 124 11 0.00 0.00 - - - - - - -
Total Operating Expenses		 435 451 399 343 262 207 128 93 54 28 12
Selling, General & Admin Expense		 153 107 104 84 60 41 28 21 27 12 8.19
Research & Development Expense		 282 344 295 259 202 166 100 72 27 15 3.85
Total Other Income / (Expense), net		 20 13 2.99 0.45 2.36 9.32 4.68 0.81 0.75 0.20 0.01
Interest & Investment Income		 20 13 2.99 0.45 2.36 9.32 4.68 0.81 0.75 0.20 0.01
Income Tax Expense		 -2.83 -3.48 0.00 0.00 - - - - - - -
Basic Earnings per Share		 ($1.28) ($1.89) ($2.49) ($2.23) ($1.88) ($1.59) ($1.27) ($1.41) ($1.85) ($0.62) ($0.48)
Weighted Average Basic Shares Outstanding		 289.88M 235.13M 159.26M 153.41M 138.30M 124.34M 97.28M 65.24M 55.27M 44.41M 24.99M
Diluted Earnings per Share		 ($1.28) ($1.89) ($2.49) ($2.23) ($1.88) ($1.59) ($1.27) ($1.41) ($1.85) ($0.62) ($0.48)
Weighted Average Diluted Shares Outstanding		 289.88M 235.13M 159.26M 153.41M 138.30M 124.34M 97.28M 65.24M 55.27M 44.41M 24.99M
Weighted Average Basic & Diluted Shares Outstanding		 327.88M 279.31M 224.24M 157.17M 138.30M 124.34M 97.28M 65.24M 55.27M 44.41M 24.99M

Quarterly Income Statements for Iovance Biotherapeutics

This table shows Iovance Biotherapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -79 -84 -97 -113 -116 -114 -107 -107 -105 -100
Consolidated Net Income / (Loss)		 -79 -84 -97 -113 -116 -114 -107 -107 -105 -100
Net Income / (Loss) Continuing Operations		 -79 -84 -97 -113 -116 -114 -107 -107 -105 -100
Total Pre-Tax Income 		-77 -85 -99 -114 -118 -115 -107 -107 -105 -100
Total Operating Income		 -87 -89 -102 -118 -121 -118 -110 -111 -107 -100
Total Gross Profit		 28 19 -0.26 -6.55 -3.88 -3.87 -1.81 0.00 - 0.00
Total Revenue		 74 59 31 0.72 0.48 0.47 0.24 0.00 - 0.00
Operating Revenue		 74 59 31 0.72 0.48 0.47 0.24 0.00 - 0.00
Total Cost of Revenue		 46 40 31 7.26 4.37 4.34 2.05 0.00 - 0.00
Operating Cost of Revenue		 46 40 31 7.26 4.37 4.34 2.05 0.00 - 0.00
Total Operating Expenses		 115 108 102 111 117 114 108 111 107 100
Selling, General & Admin Expense		 43 40 40 31 30 27 22 28 26 28
Research & Development Expense		 72 68 62 80 87 88 86 83 81 73
Total Other Income / (Expense), net		 9.58 4.01 3.36 3.34 3.12 3.36 3.08 3.49 1.72 0.78
Interest & Investment Income		 9.58 4.01 3.36 3.34 3.12 3.36 3.08 3.49 1.72 0.78
Income Tax Expense		 1.56 -1.52 -1.46 -1.41 -1.76 -1.24 -0.48 0.00 - 0.00
Basic Earnings per Share		 ($0.24) ($0.28) ($0.34) ($0.42) ($0.46) ($0.46) ($0.47) ($0.50) ($0.65) ($0.63)
Weighted Average Basic Shares Outstanding		 289.88M 303.27M 284.82M 266.22M 235.13M 245.82M 224.48M 213.69M 159.26M 157.82M
Diluted Earnings per Share		 ($0.24) ($0.28) ($0.34) ($0.42) ($0.46) ($0.46) ($0.47) ($0.50) ($0.65) ($0.63)
Weighted Average Diluted Shares Outstanding		 289.88M 303.27M 284.82M 266.22M 235.13M 245.82M 224.48M 213.69M 159.26M 157.82M
Weighted Average Basic & Diluted Shares Outstanding		 327.88M 304.78M 303.51M 279.83M 279.31M 255.92M 247.78M 224.45M 224.24M 157.84M

Annual Cash Flow Statements for Iovance Biotherapeutics

This table details how cash moves in and out of Iovance Biotherapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Net Change in Cash & Equivalents		 -59 -57 154 11 53 -63 -63 39 73 -11 25
Net Cash From Operating Activities		 -353 -362 -293 -228 -205 -159 -101 -79 -33 -18 -8.63
Net Cash From Continuing Operating Activities		 -353 -362 -293 -227 -205 -159 -101 -79 -33 -18 -8.63
Net Income / (Loss) Continuing Operations		 -372 -444 -396 -342 -260 -198 -124 -92 -53 -28 -12
Consolidated Net Income / (Loss)		 -372 -444 -396 -342 -260 -198 -124 -92 -53 -28 -12
Depreciation Expense		 12 12 9.31 3.11 1.14 1.17 0.96 0.95 0.98 1.00 0.09
Amortization Expense		 21 18 12 17 9.44 3.53 -1.33 0.02 -0.07 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 99 52 84 70 29 18 20 12 19 8.52 3.81
Changes in Operating Assets and Liabilities, net		 -113 0.79 -2.89 25 14 16 2.67 0.42 0.42 -0.24 -0.50
Net Cash From Investing Activities		 -96 -155 256 0.13 -318 90 -386 59 8.89 -71 -1.59
Net Cash From Continuing Investing Activities		 -96 -155 256 0.13 -318 90 -386 59 8.89 -71 -1.59
Purchase of Property, Plant & Equipment		 -11 -22 -20 -38 -47 -6.92 -1.20 -1.03 -1.52 -1.14 -1.59
Acquisitions		 -53 -213 0.00 0.00 - - - - - - -
Purchase of Investments		 -461 -206 -246 -725 -948 -418 -426 - -110 -141 0.00
Sale and/or Maturity of Investments		 428 286 523 763 677 515 41 60 121 71 0.00
Net Cash From Financing Activities		 391 463 190 239 576 6.13 424 59 97 78 35
Net Cash From Continuing Financing Activities		 391 463 190 239 576 6.13 424 59 97 78 35
Issuance of Common Equity		 400 466 191 205 567 0.00 399 - 96 68 32
Other Financing Activities, net		 -9.59 -2.73 -1.01 34 9.38 6.13 26 59 1.22 9.96 3.22
Effect of Exchange Rate Changes		 -0.54 -2.74 0.00 0.00 - - - - - - -

Quarterly Cash Flow Statements for Iovance Biotherapeutics

This table details how cash moves in and out of Iovance Biotherapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -48 -65 94 -41 -153 38 -253 312 113 10
Net Cash From Operating Activities		 -73 -59 -98 -122 -84 -84 -94 -100 -78 -64
Net Cash From Continuing Operating Activities		 -73 -59 -98 -122 -84 -83 -95 -100 -78 -64
Net Income / (Loss) Continuing Operations		 -79 -84 -97 -113 -116 -114 -107 -107 -105 -100
Consolidated Net Income / (Loss)		 -79 -84 -97 -113 -116 -114 -107 -107 -105 -100
Depreciation Expense		 2.98 3.03 2.99 2.98 2.95 2.92 2.93 2.76 2.81 2.45
Amortization Expense		 5.94 5.46 5.38 4.59 5.04 5.93 5.03 1.96 2.24 2.88
Non-Cash Adjustments To Reconcile Net Income		 21 31 33 14 12 9.48 18 13 19 20
Changes in Operating Assets and Liabilities, net		 -24 -15 -43 -31 13 12 -14 -10 3.37 10
Net Cash From Investing Activities		 24 -49 40 -112 -73 -79 -157 153 0.46 74
Net Cash From Continuing Investing Activities		 24 -49 40 -112 -73 -79 -157 153 0.46 74
Purchase of Property, Plant & Equipment		 -4.17 -2.29 -0.44 -4.17 -3.53 -3.58 -9.52 -5.66 -3.02 -1.39
Purchase of Investments		 -88 -157 -74 -142 -108 -93 - -5.32 -96 -64
Sale and/or Maturity of Investments		 116 110 115 87 38 21 62 164 99 139
Net Cash From Financing Activities		 2.31 42 153 194 0.96 203 1.03 258 191 0.23
Net Cash From Continuing Financing Activities		 2.31 42 153 194 0.96 203 1.03 258 191 0.23
Issuance of Common Equity		 1.39 48 153 198 1.14 203 1.27 260 191 -
Other Financing Activities, net		 0.92 -5.56 -0.61 -4.34 -0.18 -0.38 -0.25 -1.93 - 0.23
Effect of Exchange Rate Changes		 -1.18 1.25 -0.13 -0.49 3.02 -1.99 -3.77 0.00 - -

Annual Balance Sheets for Iovance Biotherapeutics

This table presents Iovance Biotherapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Total Assets		 910 780 664 777 768 345 481 155 172 106 47
Total Current Assets		 457 308 479 508 636 316 475 149 170 104 45
Cash & Equivalents		 116 115 232 78 67 14 82 145 107 34 45
Short-Term Investments		 208 165 240 426 562 293 386 0.00 60 70 0.00
Accounts Receivable		 69 0.15 0.00 - - - - - - - -
Inventories, net		 52 10 0.00 - - - - - - - -
Prepaid Expenses		 12 17 7.27 3.55 6.66 9.41 6.85 3.92 3.04 0.28 0.07
Plant, Property, & Equipment, net		 109 114 105 101 59 8.54 2.68 2.45 2.37 1.68 1.53
Total Noncurrent Assets		 344 358 73 71 73 20 2.76 3.63 0.00 0.00 0.00
Intangible Assets		 282 229 0.00 - - - - - - - -
Other Noncurrent Operating Assets		 62 129 73 71 73 20 2.76 3.63 0.00 - -
Total Liabilities & Shareholders' Equity		 910 780 664 777 768 345 481 155 172 106 47
Total Liabilities		 200 196 164 156 112 46 15 9.89 4.97 1.63 1.66
Total Current Liabilities		 122 110 91 89 55 39 14 9.60 4.97 1.63 1.66
Accounts Payable		 28 33 27 27 14 16 2.74 1.23 0.86 0.96 1.33
Accrued Expenses		 82 69 52 57 35 16 12 8.36 4.11 0.67 0.33
Other Current Liabilities		 13 7.78 13 5.06 6.28 7.25 - - - - -
Total Noncurrent Liabilities		 78 85 73 66 57 6.60 0.23 0.30 0.00 0.00 0.00
Long-Term Debt		 1.00 1.00 1.00 1.00 0.00 - - - - - -
Noncurrent Deferred & Payable Income Tax Liabilities		 32 17 0.00 - - - - - - - -
Other Noncurrent Operating Liabilities		 44 67 72 65 57 6.60 0.23 - - - -
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 710 585 500 622 656 299 466 145 167 104 45
Total Preferred & Common Equity		 710 585 500 622 656 299 466 145 167 104 45
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.01 - - - 0.00
Total Common Equity		 710 585 500 622 656 299 466 145 167 104 45
Common Stock		 3,096 2,594 2,069 1,795 1,487 869 839 395 324 208 121
Retained Earnings		 -2,385 -2,012 -1,568 -1,172 -830 -571 -373 -249 -157 -104 -77
Accumulated Other Comprehensive Income / (Loss)		 -1.05 2.53 -0.90 -0.60 0.02 0.22 -0.04 0.00 0.03 0.05 0.00

Quarterly Balance Sheets for Iovance Biotherapeutics

This table presents Iovance Biotherapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 991 964 870 852 757 825 546
Total Current Assets		 499 482 386 383 275 638 370
Cash & Equivalents		 164 229 134 268 230 543 118
Short-Term Investments		 233 184 222 94 21 83 242
Accounts Receivable		 56 32 0.23 - 0.03 - -
Inventories, net		 39 28 18 9.20 9.72 - -
Prepaid Expenses		 6.74 10 11 12 14 11 9.71
Plant, Property, & Equipment, net		 113 111 112 113 113 110 101
Total Noncurrent Assets		 380 371 366 357 303 71 69
Intangible Assets		 307 295 294 224 236 - -
Other Noncurrent Operating Assets		 73 76 72 133 68 71 69
Total Liabilities & Shareholders' Equity		 991 964 870 852 757 825 546
Total Liabilities		 218 196 190 178 179 158 152
Total Current Liabilities		 118 94 83 91 89 87 79
Accounts Payable		 32 20 26 19 31 32 24
Accrued Expenses		 75 62 46 61 47 43 48
Other Current Liabilities		 12 11 11 10 11 13 7.17
Total Noncurrent Liabilities		 100 102 107 87 90 71 73
Long-Term Debt		 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Noncurrent Deferred & Payable Income Tax Liabilities		 32 32 33 18 20 - -
Other Noncurrent Operating Liabilities		 66 69 72 68 69 70 72
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 773 769 680 674 579 667 394
Total Preferred & Common Equity		 773 769 680 674 579 667 394
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 773 769 680 674 579 667 394
Common Stock		 3,063 2,990 2,805 2,579 2,360 2,343 1,859
Retained Earnings		 -2,306 -2,222 -2,125 -1,896 -1,782 -1,676 -1,463
Accumulated Other Comprehensive Income / (Loss)		 16 0.53 0.12 -9.10 0.33 -0.13 -2.04

Annual Metrics And Ratios for Iovance Biotherapeutics

This table displays calculated financial ratios and metrics derived from Iovance Biotherapeutics' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 13,698.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 16.03% -14.25% -16.91% -28.39% -24.33% -57.17% -39.96% -74.28% -96.33% -124.72% 52.05%
EBIT Growth		 14.17% -15.46% -16.39% -30.83% -26.62% -61.29% -38.09% -73.15% -92.53% -131.38% 51.71%
NOPAT Growth		 14.17% -15.46% -16.39% -30.83% -26.62% -61.29% -38.09% -73.15% -92.53% -131.38% 46.82%
Net Income Growth		 16.18% -12.16% -15.67% -31.85% -31.40% -59.86% -34.23% -74.05% -91.23% -129.83% 52.58%
EPS Growth		 32.28% 24.10% -11.66% -18.62% -18.24% -25.20% 9.93% 23.78% -198.39% -29.17% 86.17%
Operating Cash Flow Growth		 2.44% -23.59% -28.44% -11.12% -29.11% -56.93% -28.64% -140.94% -77.73% -112.92% -135.81%
Free Cash Flow Firm Growth		 40.81% -115.58% -20.39% -6.81% -57.18% -59.18% -35.05% -71.67% -89.41% -90.63% 42.39%
Invested Capital Growth		 26.78% 1,267.20% 8.68% -23.96% 433.67% -248.07% -2,257.41% -75.89% 38.70% 604.69% 96.91%
Revenue Q/Q Growth		 80.58% 68.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 8.96% -2.69% -2.12% -41.10% 18.77% -12.59% -8.25% -12.47% -16.50% -14.33% 35.89%
EBIT Q/Q Growth		 8.07% -3.19% -1.93% -35.56% 17.49% -17.07% -7.43% -12.27% -16.11% -14.89% 35.51%
NOPAT Q/Q Growth		 8.07% -3.19% -1.93% -35.56% 17.49% -17.07% -7.43% -12.27% -16.11% -14.89% 35.51%
Net Income Q/Q Growth		 9.22% -2.55% -1.54% -9.94% -1.90% -18.61% -5.75% -12.41% -16.08% -14.45% 35.52%
EPS Q/Q Growth		 14.67% 9.13% -0.40% -8.78% 2.59% -18.66% 7.30% -2.17% -8.82% -21.57% 52.94%
Operating Cash Flow Q/Q Growth		 2.94% -1.77% -8.86% 3.73% -4.52% -16.30% -11.68% -12.60% -20.60% -21.60% -14.04%
Free Cash Flow Firm Q/Q Growth		 1.57% -1.31% -9.16% -4.24% 3.62% -13.29% -15.43% -7.57% -203.80% 46.70% 25.62%
Invested Capital Q/Q Growth		 2.83% -2.52% -20.51% -53.90% 1,273.00% -19.07% 60.10% -94.76% 396.69% -98.37% 88.47%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 24.43% -804.54% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -220.60% -36,252.06% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -240.92% -38,734.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -240.92% -38,734.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -226.84% -37,345.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.25% 99.22% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 94.87% 97.17% 99.25% 99.87% 99.10% 95.50% 96.35% 99.12% 98.61% 99.28% 99.95%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -79.81% -196.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -48.07% -164.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 22.33% 114.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -57.48% -81.91% -70.61% -53.55% -54.34% -51.64% -40.41% -58.94% -39.04% -37.16% -38.54%
Cash Return on Invested Capital (CROIC)		 -103.43% -369.25% -1,308.81% -979.92% -807.53% 0.00% 0.00% -23,263.99% -9,772.32% -6,157.59% 0.00%
Operating Return on Assets (OROA)		 -46.76% -63.77% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -44.02% -61.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -57.48% -81.91% -70.61% -53.55% -54.34% -51.64% -40.41% -58.94% -39.04% -37.16% -38.54%
Return on Equity Simple (ROE_SIMPLE)		 -52.39% -75.95% -79.24% -55.05% -39.54% -66.08% -26.51% -63.28% -31.69% -26.59% -26.84%
Net Operating Profit after Tax (NOPAT)		 -277 -322 -279 -240 -183 -145 -90 -65 -38 -20 -8.43
NOPAT Margin		 -168.64% -27,114.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -31.74% -32.18% -21.64% -16.64% -16.28% -13.60% -11.01% -17.35% -11.36% -10.98% -11.17%
Return On Investment Capital (ROIC_SIMPLE)		 -38.89% -55.05% -55.77% - - - - - - - -
Cost of Revenue to Revenue		 75.57% 904.54% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 93.26% 8,992.09% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 172.08% 28,938.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 265.35% 37,930.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -395 -461 -399 -343 -262 -207 -128 -93 -54 -28 -12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -362 -431 -377 -323 -251 -202 -129 -92 -53 -27 -12
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.17 3.56 2.02 4.82 10.37 11.68 2.34 3.99 2.59 3.55 4.85
Price to Tangible Book Value (P/TBV)		 5.27 5.86 2.02 4.82 10.37 11.68 2.34 3.99 2.59 3.55 4.85
Price to Revenue (P/Rev)		 13.75 1,749.89 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 4.99 5.89 23.76 121.10 228.26 0.00 0.00 4,034.16 591.59 822.22 0.00
Enterprise Value to Revenue (EV/Rev)		 11.78 1,515.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.46 -0.70 -0.96 -0.96 -0.98 -1.01 -1.00 -1.00 -1.00 -1.00 -1.03
Leverage Ratio		 1.31 1.33 1.29 1.21 1.17 1.08 1.04 1.05 1.02 1.02 1.06
Compound Leverage Factor		 1.24 1.29 1.28 1.21 1.15 1.03 1.00 1.04 1.01 1.01 1.06
Debt to Total Capital		 0.14% 0.17% 0.20% 0.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.14% 0.17% 0.20% 0.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.86% 99.83% 99.80% 99.84% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.89 0.65 1.27 1.56 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 1.17 0.87 1.71 2.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 2.29 1.13 -0.91 8.62 34.75 42.54 43.90 32.11 50.95 134.84 76.49
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.74 2.79 5.24 5.69 11.59 8.10 33.02 15.56 34.12 63.79 27.06
Quick Ratio		 3.21 2.54 5.16 5.65 11.47 7.86 32.54 15.15 33.51 63.62 27.02
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -359 -606 -281 -233 -219 -139 -87 -65 -38 -20 -10
Operating Cash Flow to CapEx		 -3,188.88% -1,623.24% -1,433.33% -606.65% -438.40% -2,297.08% -8,451.50% -7,656.52% -2,147.80% -1,608.14% -542.27%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 4.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 4.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.47 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 4.09 0.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 77.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 91.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 89.24 1,013.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 79.15 -1,013.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 388 306 22 21 27 -8.11 -2.33 0.11 0.45 0.32 -0.06
Invested Capital Turnover		 0.47 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 82 283 1.79 -6.48 35 -5.78 -2.44 -0.34 0.13 0.39 2.00
Enterprise Value (EV)		 1,933 1,802 531 2,492 6,177 3,186 622 436 265 266 173
Market Capitalization		 2,255 2,081 1,009 2,995 6,806 3,493 1,090 581 432 369 218
Book Value per Share		 $2.33 $2.28 $3.17 $3.96 $4.48 $2.37 $3.78 $2.00 $2.69 $2.17 $1.62
Tangible Book Value per Share		 $1.40 $1.39 $3.17 $3.96 $4.48 $2.37 $3.78 $2.00 $2.69 $2.17 $1.62
Total Capital		 711 586 501 623 656 299 466 145 167 104 45
Total Debt		 1.00 1.00 1.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 1.00 1.00 1.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -323 -279 -477 -503 -629 -307 -469 -145 -166 -104 -45
Capital Expenditures (CapEx)		 11 22 20 38 47 6.92 1.20 1.03 1.52 1.14 1.59
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 11 -82 -91 -86 -48 -30 -7.55 -5.68 -1.93 -1.35 -1.60
Debt-free Net Working Capital (DFNWC)		 335 198 388 419 581 277 461 140 165 102 43
Net Working Capital (NWC)		 335 198 388 419 581 277 461 140 165 102 43
Net Nonoperating Expense (NNE)		 95 122 117 102 76 53 34 27 15 8.16 3.61
Net Nonoperating Obligations (NNO)		 -323 -279 -477 -601 -629 -307 -469 -145 -166 -104 -45
Total Depreciation and Amortization (D&A)		 33 30 22 20 11 4.70 -0.38 0.97 0.90 1.00 0.09
Debt-free, Cash-free Net Working Capital to Revenue		 6.64% -6,923.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 203.98% 16,614.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 203.98% 16,614.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.28) ($1.89) ($2.49) ($2.23) ($1.88) ($1.59) ($1.27) ($1.41) ($1.85) ($0.62) ($0.48)
Adjusted Weighted Average Basic Shares Outstanding		 289.88M 235.13M 159.26M 153.41M 146.98M 126.50M 123.42M 89.45M 62.31M 48.57M 44.08M
Adjusted Diluted Earnings per Share		 ($1.28) ($1.89) ($2.49) ($2.23) ($1.88) ($1.59) ($1.27) ($1.41) ($1.85) ($0.62) ($0.48)
Adjusted Weighted Average Diluted Shares Outstanding		 289.88M 235.13M 159.26M 153.41M 146.98M 126.50M 123.42M 89.45M 62.31M 48.57M 44.08M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($1.88) ($1.59) ($1.27) ($1.41) ($1.85) ($0.62) ($0.48)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 327.88M 279.31M 224.24M 157.17M 138.30M 124.34M 97.28M 65.24M 55.27M 44.41M 24.99M
Normalized Net Operating Profit after Tax (NOPAT)		 -277 -322 -279 -240 -183 -145 -90 -65 -38 -20 -8.43
Normalized NOPAT Margin		 -168.64% -27,114.49% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -228.56% -37,638.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Iovance Biotherapeutics

This table displays calculated financial ratios and metrics derived from Iovance Biotherapeutics' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 15,189.21% 12,385.07% 12,969.75% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 31.44% 26.42% 8.39% -3.78% -11.07% -15.20% -8.60% -23.14% -8.30% -17.41%
EBIT Growth		 28.60% 24.75% 7.42% -6.19% -13.29% -17.90% -10.38% -20.87% -7.61% -16.41%
NOPAT Growth		 28.60% 24.75% 7.42% -6.19% -13.29% -17.90% -10.38% -20.87% -7.61% -16.41%
Net Income Growth		 32.50% 26.56% 8.85% -5.22% -10.50% -14.20% -7.23% -17.21% -6.03% -15.67%
EPS Growth		 47.83% 39.13% 27.66% 16.00% 29.23% 26.98% 25.40% 13.79% -1.56% -14.55%
Operating Cash Flow Growth		 12.71% 29.86% -4.77% -22.51% -8.11% -32.10% -21.02% -35.25% -44.24% -10.32%
Free Cash Flow Firm Growth		 61.31% 65.88% 42.77% -424.93% -380.06% -584.98% -280.23% -10.52% -21.49% 49.89%
Invested Capital Growth		 26.78% 20.19% 36.10% 805.60% 1,267.20% 1,014.83% 432.67% -18.43% 8.68% -36.97%
Revenue Q/Q Growth		 25.85% 88.24% 4,250.49% 48.34% 2.77% 97.06% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 3.61% 13.87% 15.07% 2.75% -3.43% -7.23% 3.78% -4.07% -7.28% -1.09%
EBIT Q/Q Growth		 2.80% 12.61% 13.43% 2.91% -2.45% -7.52% 0.69% -3.57% -6.61% -0.66%
NOPAT Q/Q Growth		 2.80% 12.61% 13.43% 2.91% -2.45% -7.52% 0.69% -3.57% -6.61% -0.66%
Net Income Q/Q Growth		 5.96% 13.96% 14.05% 2.92% -2.30% -6.79% 0.78% -1.95% -5.72% -0.27%
EPS Q/Q Growth		 14.29% 17.65% 19.05% 8.70% 0.00% 2.13% 6.00% 23.08% -3.17% 0.00%
Operating Cash Flow Q/Q Growth		 -24.29% 40.09% 19.50% -45.62% 0.13% 10.50% 5.87% -28.51% -22.03% 18.02%
Free Cash Flow Firm Q/Q Growth		 -13.37% 24.30% 54.60% 0.71% 0.02% -26.99% -316.44% 9.20% -42.65% 29.51%
Invested Capital Q/Q Growth		 2.83% 5.62% 12.10% 4.14% -2.52% 19.60% 645.88% 57.22% -20.51% -42.86%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 38.20% 31.99% -0.84% -915.52% -805.60% -825.37% -761.34% 0.00% 0.00% 0.00%
EBITDA Margin		 -105.38% -137.60% -300.74% -15,405.59% -23,499.79% -23,349.47% -42,908.40% 0.00% 0.00% 0.00%
Operating Margin		 -117.48% -152.11% -327.63% -16,464.62% -25,156.85% -25,236.89% -46,254.62% 0.00% 0.00% 0.00%
EBIT Margin		 -117.48% -152.11% -327.63% -16,464.62% -25,156.85% -25,236.89% -46,254.62% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -106.60% -142.67% -312.16% -15,800.84% -24,145.02% -24,255.86% -44,759.66% 0.00% 0.00% 0.00%
Tax Burden Percent		 102.02% 98.21% 98.52% 98.77% 98.51% 98.92% 99.55% 100.00% 100.00% 100.00%
Interest Burden Percent		 88.94% 95.50% 96.71% 97.16% 97.43% 97.16% 97.20% 96.86% 98.40% 99.23%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -38.92% -28.02% -24.28% -124.13% -127.63% -73.09% -49.48% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -32.95% -22.42% -17.20% -117.98% -119.30% -64.57% -41.51% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 15.31% 11.72% 9.29% 87.01% 83.20% 43.91% 29.21% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -23.61% -16.30% -14.98% -37.12% -44.43% -29.18% -20.27% -67.55% -70.61% -71.41%
Cash Return on Invested Capital (CROIC)		 -103.43% -105.50% -134.42% -345.31% -369.25% -349.91% -329.32% -727.49% -1,308.81% -707.50%
Operating Return on Assets (OROA)		 -22.80% -14.99% -12.47% -37.00% -41.42% -25.52% -16.09% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -20.69% -14.06% -11.88% -35.51% -39.75% -24.53% -15.57% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -23.61% -16.30% -14.98% -37.12% -44.43% -29.18% -20.27% -67.55% -70.61% -71.41%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -53.01% -57.28% -66.12% 0.00% -64.24% -72.39% -61.73% 0.00% -99.03%
Net Operating Profit after Tax (NOPAT)		 -61 -62 -71 -82 -85 -83 -77 -78 -75 -70
NOPAT Margin		 -82.24% -106.47% -229.34% -11,525.23% -17,609.79% -17,665.82% -32,378.24% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.97% -5.60% -7.08% -6.16% -8.33% -8.51% -7.97% -5.22% -5.64% -5.76%
Return On Investment Capital (ROIC_SIMPLE)		 -8.52% - - - -14.49% - - - -14.97% -
Cost of Revenue to Revenue		 61.80% 68.01% 100.84% 1,015.52% 905.60% 925.37% 861.34% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 57.68% 67.55% 127.20% 4,390.63% 6,203.94% 5,749.25% 9,213.03% 0.00% 0.00% 0.00%
R&D to Revenue		 98.01% 116.55% 199.59% 11,158.46% 18,147.30% 18,662.26% 36,280.25% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 155.68% 184.10% 326.79% 15,549.09% 24,351.24% 24,411.51% 45,493.28% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -87 -89 -102 -118 -121 -118 -110 -111 -107 -100
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -78 -81 -94 -110 -113 -110 -102 -106 -102 -95
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 3.17 3.68 2.92 5.58 3.56 1.67 2.73 2.05 2.02 3.84
Price to Tangible Book Value (P/TBV)		 5.27 6.11 4.74 9.83 5.86 2.50 4.61 2.05 2.02 3.84
Price to Revenue (P/Rev)		 13.75 31.37 68.48 1,991.97 1,749.89 1,594.60 6,639.15 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 4.99 6.51 5.13 10.78 5.89 2.45 4.82 21.00 23.76 40.97
Enterprise Value to Revenue (EV/Rev)		 11.78 27.00 55.92 1,802.04 1,515.35 1,084.88 5,310.07 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.46 -0.52 -0.54 -0.74 -0.70 -0.68 -0.70 -0.94 -0.96 -0.93
Leverage Ratio		 1.31 1.27 1.28 1.26 1.33 1.31 1.30 1.25 1.29 1.26
Compound Leverage Factor		 1.16 1.22 1.24 1.22 1.30 1.27 1.27 1.21 1.26 1.25
Debt to Total Capital		 0.14% 0.13% 0.13% 0.15% 0.17% 0.15% 0.17% 0.15% 0.20% 0.25%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.14% 0.13% 0.13% 0.15% 0.17% 0.15% 0.17% 0.15% 0.20% 0.25%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.86% 99.87% 99.87% 99.85% 99.83% 99.85% 99.83% 99.85% 99.80% 99.75%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.89 1.00 0.97 0.83 0.65 0.86 0.78 1.59 1.27 0.97
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 1.17 1.32 1.28 1.11 0.87 1.15 1.05 2.16 1.71 1.31
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 3.41 4.85 3.82 8.54 2.56 0.63 1.83 2.72 0.54 2.24
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 3.74 4.22 5.15 4.63 2.79 4.21 3.10 7.31 5.24 4.67
Quick Ratio		 3.21 3.84 4.74 4.28 2.54 3.97 2.83 7.18 5.16 4.55
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -142 -126 -166 -366 -368 -368 -290 -70 -77 -54
Operating Cash Flow to CapEx		 -1,758.54% -2,577.49% -22,269.00% -2,931.65% -2,379.43% -2,350.66% -986.89% -1,762.27% -2,570.19% -4,588.97%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.19 0.10 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 4.72 0.00 2.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 4.01 3.47 2.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.47 0.81 0.29 0.02 0.01 0.01 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 4.09 3.25 1.84 0.63 0.36 0.29 0.08 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 77.30 0.00 176.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 91.09 105.28 144.87 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 89.24 112.30 198.84 580.16 1,013.48 1,243.20 4,555.02 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 79.15 -7.02 122.21 -580.16 -1,013.48 -1,243.20 -4,555.02 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 388 377 357 318 306 314 262 35 22 28
Invested Capital Turnover		 0.47 0.26 0.11 0.01 0.01 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 82 63 95 283 283 286 213 -7.94 1.79 -17
Enterprise Value (EV)		 1,933 2,454 1,833 3,431 1,802 767 1,264 738 531 1,153
Market Capitalization		 2,255 2,850 2,244 3,793 2,081 1,127 1,580 1,370 1,009 1,512
Book Value per Share		 $2.33 $2.55 $2.75 $2.55 $2.28 $2.72 $2.58 $2.97 $3.17 $2.50
Tangible Book Value per Share		 $1.40 $1.54 $1.69 $1.45 $1.39 $1.82 $1.53 $2.97 $3.17 $2.50
Total Capital		 711 774 770 681 586 675 580 668 501 395
Total Debt		 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Total Long-Term Debt		 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Net Debt		 -323 -396 -412 -362 -279 -360 -316 -632 -477 -359
Capital Expenditures (CapEx)		 4.17 2.29 0.44 4.17 3.53 3.58 9.52 5.66 3.02 1.39
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 11 -17 -24 -60 -82 -70 -131 -82 -91 -70
Debt-free Net Working Capital (DFNWC)		 335 381 389 302 198 292 186 551 388 291
Net Working Capital (NWC)		 335 381 389 302 198 292 186 551 388 291
Net Nonoperating Expense (NNE)		 18 21 26 31 31 31 29 30 30 29
Net Nonoperating Obligations (NNO)		 -323 -396 -412 -362 -279 -360 -316 -632 -477 -366
Total Depreciation and Amortization (D&A)		 8.92 8.49 8.37 7.57 7.99 8.85 7.96 4.72 5.05 5.34
Debt-free, Cash-free Net Working Capital to Revenue		 6.64% -18.67% -73.23% -3,167.33% -6,923.89% -9,864.64% -55,079.41% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 203.98% 418.81% 1,185.82% 15,878.10% 16,614.13% 41,249.08% 78,250.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 203.98% 418.81% 1,185.82% 15,878.10% 16,614.13% 41,249.08% 78,250.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.24) ($0.28) ($0.34) ($0.42) ($0.46) ($0.46) ($0.47) ($0.50) ($0.65) ($0.63)
Adjusted Weighted Average Basic Shares Outstanding		 289.88M 303.27M 284.82M 266.22M 235.13M 245.82M 224.48M 213.69M 159.26M 157.82M
Adjusted Diluted Earnings per Share		 ($0.24) ($0.28) ($0.34) ($0.42) ($0.46) ($0.46) ($0.47) ($0.50) ($0.65) ($0.63)
Adjusted Weighted Average Diluted Shares Outstanding		 289.88M 303.27M 284.82M 266.22M 235.13M 245.82M 224.48M 213.69M 159.26M 157.82M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 327.88M 304.78M 303.51M 279.83M 279.31M 255.92M 247.78M 224.45M 224.24M 157.84M
Normalized Net Operating Profit after Tax (NOPAT)		 -61 -62 -71 -82 -85 -83 -77 -78 -75 -70
Normalized NOPAT Margin		 -82.24% -106.47% -229.34% -11,525.23% -17,609.79% -17,665.82% -32,378.24% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -104.49% -145.27% -316.85% -15,997.76% -24,509.96% -24,520.90% -44,960.08% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Iovance Biotherapeutics' Financials

When does Iovance Biotherapeutics's fiscal year end?

According to the most recent income statement we have on file, Iovance Biotherapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Iovance Biotherapeutics' net income changed over the last 10 years?

Iovance Biotherapeutics' net income appears to be on an upward trend, with a most recent value of -$372.18 million in 2024, rising from -$12.04 million in 2014. The previous period was -$444.04 million in 2023. See Iovance Biotherapeutics' forecast for analyst expectations on what’s next for the company.

What is Iovance Biotherapeutics's operating income?
Iovance Biotherapeutics's total operating income in 2024 was -$395.28 million, based on the following breakdown:
  • Total Gross Profit: $40.08 million
  • Total Operating Expenses: $435.35 million
How has Iovance Biotherapeutics revenue changed over the last 10 years?

Over the last 10 years, Iovance Biotherapeutics' total revenue changed from $0.00 in 2014 to $164.07 million in 2024, a change of 16,407,000,000.0%.

How much debt does Iovance Biotherapeutics have?

Iovance Biotherapeutics' total liabilities were at $200.02 million at the end of 2024, a 2.2% increase from 2023, and a 11,935.0% increase since 2014.

How much cash does Iovance Biotherapeutics have?

In the past 10 years, Iovance Biotherapeutics' cash and equivalents has ranged from $13.97 million in 2019 to $231.73 million in 2022, and is currently $115.69 million as of their latest financial filing in 2024.

How has Iovance Biotherapeutics' book value per share changed over the last 10 years?

Over the last 10 years, Iovance Biotherapeutics' book value per share changed from 1.62 in 2014 to 2.33 in 2024, a change of 43.7%.


Related Companies

This page (NASDAQ:IOVA) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsored